Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed) | PAR 20 165

Funding Opportunity FAQs: PAR-20-165 - Research on ME/CFS (R01 Clinical Trials Not Allowed)

What is PAR-20-165?

PAR-20-165 is a National Institutes of Health (NIH) funding opportunity titled "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)." It supports investigator-initiated research projects that aim to expand scientific understanding of ME/CFS.

What grant mechanism does this opportunity use?

This opportunity uses the NIH R01 grant mechanism, which supports discrete, specified research projects proposed by investigators.

Are clinical trials allowed under this FOA?

No. This FOA explicitly states that clinical trials are not allowed.

What is the overall purpose of this funding opportunity?

The purpose is to expand scientific understanding of ME/CFS by supporting studies focused on causes (etiology), identification and diagnosis, underlying biological dysfunctions (pathophysiology), and the range of symptoms and impacts (manifestations). The long-term intent is to support knowledge that can lead to more accurate diagnosis, better approaches to care, and improved quality of life for people living with ME/CFS.

What research topics does NIH emphasize in this FOA?

The FOA emphasizes research that addresses major gaps in the ME/CFS field, including studies of environmental and biological risk factors, determinants of heterogeneity (why the illness differs across individuals), and shared mechanisms that may affect multiple body systems simultaneously.

What does the FOA mean by "etiology" in the context of ME/CFS research?

In this FOA, etiology refers to research examining potential causes of ME/CFS, including environmental and biological risk factors that may contribute to developing the illness.

What does the FOA mean by improving "identification and diagnosis"?

It refers to research that strengthens how ME/CFS can be recognized and diagnosed, potentially including the development or validation of measurable indicators such as biomarkers that could support more accurate diagnosis or subgroup identification.

What kinds of "pathophysiology" questions is NIH looking for?

The FOA prioritizes research that clarifies underlying biological dysfunctions in ME/CFS, including mechanisms that may drive multi-system involvement and how different organ systems respond pathophysiologically in individuals with ME/CFS.

What are "manifestations" of ME/CFS as described here?

Manifestations refer to the symptoms, clinical presentation, and broader impacts of ME/CFS, including how those impacts may vary across individuals.

What does NIH mean by "determinants of heterogeneity"?

This refers to research aimed at explaining why ME/CFS can look very different from one person to another, such as factors that may define subgroups, influence symptom patterns, or shape multi-system involvement.

Does the FOA encourage multi-system research?

Yes. The FOA highlights the multi-system nature of ME/CFS and prioritizes work that clarifies shared mechanisms potentially affecting multiple body systems at once.

Does NIH encourage research across different ages and populations?

Yes. The FOA prioritizes research designed to span diverse groups and the full lifespan and encourages studies that consider differences related to age, background, and other population factors.

Is interdisciplinary or team-based research encouraged?

Yes. Interdisciplinary, team-based science is a major focus. NIH signals particular interest in projects that bring together researchers across fields to better characterize disease processes and develop evidence-based solutions.

Does the FOA support biomarker research?

Yes. The FOA explicitly mentions interest in building teams to study and develop biomarkers, described as measurable indicators that could help confirm diagnosis or stratify subgroups.

What does the FOA say about innovation?

The FOA encourages novel, innovative ideas that break new ground or extend prior discoveries into new directions, rather than simply repeating established approaches.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. and non-U.S. organizations, including government entities, institutions of higher education, nonprofits, for-profits (including small businesses), tribal governments and organizations, public housing authorities/Indian housing authorities, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities.

Are non-U.S. (foreign) organizations eligible?

Yes. The FOA explicitly includes non-domestic (non-U.S.) entities (foreign organizations) among eligible applicants.

Are tribal governments and tribal organizations eligible?

Yes. Eligible applicants include federally recognized Native American tribal governments, tribal organizations, and other tribal governments that are not federally recognized.

Are minority-serving institutions specifically included?

Yes. The FOA explicitly notes additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).

Are faith-based or community-based organizations eligible?

Yes. The FOA explicitly includes faith-based or community-based organizations among additional eligible applicant categories.

Are for-profit organizations eligible?

Yes. For-profit organizations (other than small businesses) and small businesses are listed as eligible applicants.

Are nonprofits eligible even if they do not have 501(c)(3) status?

Yes. The eligibility list includes nonprofits with or without 501(c)(3) status (outside of higher education).

What type of funding is this categorized as?

The opportunity is categorized as discretionary funding and uses a grant funding instrument type.

What activity areas does this FOA cover?

The activity areas are listed as education, environment, and health.

Are multiple NIH institutes or centers involved?

Yes. Multiple CFDA numbers are associated with the announcement, reflecting involvement of different NIH institutes and centers and the cross-cutting nature of ME/CFS research.

What CFDA numbers are associated with this FOA?

The provided CFDA numbers are: 93.113, 93.121, 93.213, 93.233, 93.242, 93.273, 93.350, 93.837, 93.838, 93.839, 93.840, 93.846, 93.853, 93.855, and 93.879.

Is there an award ceiling listed?

No award ceiling is specified in the provided details.

Is the expected number of awards listed?

No. The provided details do not specify an expected number of awards.

What does it mean that no award ceiling or number of awards is provided?

Based on the provided description, it means those specifics are not stated in the details shared here. The description notes that applicants often rely on standard NIH R01 budgeting rules, institute-specific guidance, and the FOA text for constraints or expectations.

When was this funding opportunity created?

The source data indicates a creation date of 2020-04-13.

What is the original closing date listed in the provided information?

The source data indicates an original closing date of 2023-03-05.

What is the main outcome NIH is aiming for through this FOA?

The FOA aims to strengthen the ME/CFS evidence base through rigorous, innovative, collaborative research that can explain disease mechanisms, improve diagnostic tools (including biomarkers), and clarify why ME/CFS varies across people and across the lifespan, while maintaining the requirement that clinical trials are not allowed.